A Phase II Clinical Trial Evaluating Ibrutinib Maintenance Following Intensive Induction for Patients With Previously Untreated Mantle Cell Lymphoma (MCL)
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 04 Jun 2019
Price : $35 *
At a glance
- Drugs Ibrutinib (Primary)
- Indications Mantle-cell lymphoma
- Focus Therapeutic Use
- 04 Jun 2019 Preliminary results presented at the 55th Annual Meeting of the American Society of Clinical Oncology
- 13 Dec 2018 Status changed from recruiting to active, no longer recruiting.
- 28 Aug 2018 Planned End Date changed from 1 Jan 2019 to 1 Jan 2020.